Taken together, these results suggest that γδ T cells are regulated by the PD-1 signaling pathway when they are activated or they are killing tumor cells, indicating the potential benefit of combination therapy with γδ T cells and PD-1 immune checkpoint inhibitors. Here, PDCD1 is linked to neoplasm.